These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 22620015)

  • 1. [Biomarkers in the diagnosis and therapy of inflammatory bowel diseases].
    Iijima H; Shinzaki S; Tsujii M; Takehara T
    Nihon Rinsho; 2012 May; 70(5):869-73. PubMed ID: 22620015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
    Mendoza JL; Abreu MT
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease.
    Arai R
    Postgrad Med; 2010 Jul; 122(4):177-85. PubMed ID: 20675980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serologic markers in inflammatory bowel disease (IBD).
    Nakamura RM; Barry M
    MLO Med Lab Obs; 2001 Nov; 33(11):8-15; quiz 16-9. PubMed ID: 11721286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New serologic markers for inflammatory bowel disease diagnosis.
    Dotan I
    Dig Dis; 2010; 28(3):418-23. PubMed ID: 20926866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
    Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
    Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies: serologic markers in inflammatory bowel disease.
    Hartman C; Eliakim R; Shamir R
    Isr Med Assoc J; 2004 Apr; 6(4):221-6. PubMed ID: 15115261
    [No Abstract]   [Full Text] [Related]  

  • 9. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.
    Lewis JD
    Gastroenterology; 2011 May; 140(6):1817-1826.e2. PubMed ID: 21530748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in inflammatory bowel disease: current practices and recent advances.
    Iskandar HN; Ciorba MA
    Transl Res; 2012 Apr; 159(4):313-25. PubMed ID: 22424434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Established and emerging biological activity markers of inflammatory bowel disease.
    Nielsen OH; Vainer B; Madsen SM; Seidelin JB; Heegaard NH
    Am J Gastroenterol; 2000 Feb; 95(2):359-67. PubMed ID: 10685736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic biomarkers in inflammatory bowel disease].
    Kanmura S; Sakiyama T; Uto H; Tsubouchi H
    Nihon Rinsho; 2012 May; 70(5):790-5. PubMed ID: 22620002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
    Mokrowiecka A; Gasiorowska A; Małecka-Panas E
    Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Bansi DS; Chapman RW; Fleming KA
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of serological assays in pediatric inflammatory bowel disorders.
    Mainardi E; Villanacci V; Bassotti G; Liserre B; Rossi E; Incardona P; Falchetti D; Tonegatti L; Montanelli A; Barabino A; Coccia C; Gambini C
    Digestion; 2007; 75(4):210-4. PubMed ID: 17952008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological markers in inflammatory bowel disease: a review of their clinical utility.
    Barahona-Garrido J; Sarti HM; Barahona-Garrido MK; Hernández-Calleros J; Coss-Adame E; Garcia-Saenz SM; Yamamoto-Furusho JK
    Rev Gastroenterol Mex; 2009; 74(3):230-7. PubMed ID: 19858012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antineutrophil cytoplasmic antibodies in chronic inflammatory bowel diseases].
    Schlenker T; Apenberg S; Raedsch R; Andrassy K; Plachky J; Kommerell B
    Dtsch Med Wochenschr; 1992 Sep; 117(39):1463-8. PubMed ID: 1396127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.